Synthesis of Nomega-Nitro-l-arginine methyl ester modified reduced graphene oxide nanosheets and their protective action on experimental preeclampsia in mice.

The purpose of this study is to synthesize Nomega-Nitro-L-arginine methyl ester (L-NAME) adsorbed reduced graphene oxide (RGO) sheets and demonstrate their protective impact on the detrimental effect detected in investigational pre-eclampsia, a prerequisite where increase in oxidative stress and decreased Nitric Oxide (NO) production were present. The synthesized graphene sheets were studies by using various characterization techniques. Later, a prerequisite similar to pre-eclampsia has been induced through chronic inhibition of NO fabrication using a 60 mg/kg/day L-NAME, orally in pregnant mice. We observed arterial pressure increase, a decrease of alive fetus toward the end of pregnancy and insulin resistance increase in pregnant L-NAME mice and no much difference was detected in pregnant L-NAME-RGO mice. We also observed an arterial pressure increase in normal L-NAME mice. In this paper, we determined a protective impact of RGO in investigational pre-eclampsia.

Synthesis and in vivo distribution of no-carrier-added N(omega)-Nitro-L-arginine [11C]methyl ester, a nitric oxide synthase inhibitor.

N(omega)-nitro-L-arginine methyl ester (L-NAME) was labelled with carbon-11 as a potential PET tracer for NO synthase. N(alpha)-t-butoxycarbonyl-N(omega)-nitro-L-arginine was reacted with [11C]diazomethane. After deprotection with trifluoroacetic acid the formed [11C]L-NAME was purified using HPLC. Biodistribution studies in rats and PET studies in monkeys and dogs showed no correlation between radioactivity distribution and NO synthase localization in brain and heart. Substantial amounts of [11C]methanol were detected in dog plasma shortly after injection. These findings preclude the use of [11C]L-NAME as a PET tracer.